IP Group - visionary ventures

Lots of momentum across our cleantech and deeptech portfolio. 🚀 Cleantech 🌱 🔹 Mantle8 – €31m raise to advance the commercial viability of natural hydrogen 🔹 Barocal – $10m funding to scale its solid-state heating and cooling technology 🌍 🔹 @HysataH2 – redefining the economics of green hydrogen with world‑leading electrolyser efficiency. Read more in our case study here: bit.ly/4dvboi5 Deeptech ⚙️ 🔹 @quantum_motion Motion – $160m Series C to accelerate its silicon-based approach to utility-scale quantum computing 🔹 Lumai – first full AI model inference demonstrated using optical (photonic) computing 🔹 Intrinsic – developing next-generation non-volatile memory for faster, more energy-efficient computing in the AI era. Read more in our case study here: bit.ly/4wG7fki A strong set of milestones across the portfolio, spanning climate, computing and frontier technologies. 👏

📬 Our May newsletter is now live. It features the latest news from across the Group and our portfolio, including: 🔹 The appointment of Michael Queen, 3i Group plc’s former CEO, as our Chair Designate 🔬 Enterprise Therapeutics’ positive Phase 2 results in cystic fibrosis 🆕 A new portfolio company we’re excited to back – Hypervision Surgical 💰 Barocal’s $10m fundraising 👉 Read the newsletter here: bit.ly/3RQrhII ✉️ Sign up to receive future editions: bit.ly/4s0MsFd

🧬 Portfolio impact in action: @artiospharma 🔍 Artios is developing a new class of cancer therapies that target DNA Damage Response (DDR) pathways, with the potential to transform outcomes for patients with cancers that are difficult to treat. 💊 With its lead drug alnodesertib (formerly known as ART0380) now in Phase 2 clinical trials, Artios is focused on treating specific tumour subtypes where existing treatment options are limited and survival rates remain low. 🤝 @IPGroupplc has supported Artios from pre‑clinical research through to its ongoing Phase 2 study, helping to advance innovation that aims to reduce mortality, improve quality of life and deliver meaningful real‑world impact for patients. 📖 Full case study: ipgroupplc.com/our-portfolio/…

An exciting and busy few weeks in our Healthtech and Life Sciences portfolio 🔬📈 Encouraging progress across multiple portfolio companies and programmes, including: • Enterprise Therapeutics – positive results from its Phase 2 clinical trial for cystic fibrosis 🧬 • Hypervision Surgical – oversubscribed £17m Series A funding round 💰 • STORM Therapeutics – $56m Series C funding round 💰 • Artios Pharma – clinical trial collaboration with GSK 🔬 • Istesso – data highlighting leramistat’s ability to restore muscle quality beyond baseline in ageing models 💪 • Alesi Surgical – £7m funding round completed 🤝 • Centessa – being acquired by Eli Lilly and Company for an initial $6.3bn 🎯 👏

Pleased to support this €31m Series A for portfolio company Mantle8🚀Congratulations to Emmanuel Masini and the team on this important next phase 👏🌍 France’s Mantle8 raises €31 million to fund the world’s most advanced natural hydrogen exploration and drilling campaign eu-startups.com/2026/05/france… via @EU-Startups

🌱 Portfolio impact in action: @HysataH2 🔍Hysata is redefining the economics of green hydrogen by developing electrolyser technology with world‑leading efficiency to help accelerate decarbonisation in hard‑to‑abate sectors. ⚡ Hysata’s novel electrolysers deliver world-leading 95% system efficiency, which provides the lowest levelized cost of hydrogen (LCOH) and fundamentally improves the economics of green hydrogen production. This is a critical step in the global energy transition. 🤝 @IPGroupplc has supported Hysata from inception, working alongside the founding academic team to help form the company and backing its growth through to Series B. Today, Hysata is building the foundations needed to decarbonise industries such as steelmaking, chemicals, heavy transport and high‑grade heat. 📖 Full case study: ipgroupplc.com/our-portfolio/…

🧬 We’re pleased to share our portfolio company @EnterpriseThera has reported positive results from its Phase 2 clinical trial for cystic fibrosis. 👏 Congratulations to the Enterprise Therapeutics team on this encouraging progress. 👇 Read more via link in comments

💻💬Hear the IP Group plc story from our Finance Director! Chris Glasson will be presenting at the Mello Investment Trusts & Funds webinar tomorrow at 1pm. 🎟️ Register to attend: bit.ly/4dhzqNx

🚀 Congratulations to portfolio company @quantum_motion on the successful close of its $160m Series C funding round. A major milestone for the company as it continues to advance its silicon‑based approach to utility‑scale quantum computing.

IP Group CEO Greg Smith discusses the group’s asymmetric return potential, AI exposure and progress on cash realisations, alongside NAV uplift linked to Pfizer obesity-related licensing streams. $IPO @IPGroupplc 📽️ Watch full interview here: okt.to/RL2Baq

📢Delighted to announce the appointment of Michael Queen as Chair Designate. Michael will join the Board as Non‑executive Director and Chair Designate, and become Chair following the Group’s AGM on 18 June 2026.  👇 Read more via link in comments

🧠 Portfolio impact in action: Intrinsic 🔍 Intrinsic is developing next‑generation non‑volatile memory technology designed to transform how data is stored, read and written, enabling faster, more energy‑efficient computing for the AI era. ⚡ Built on more than a decade of ReRAM research at UCL, Intrinsic’s technology scales to lower nodes, is simple to manufacture, and allows integration of memory directly onto the chip, all of which help deliver significant gains in performance while reducing power consumption. This is a critical challenge as AI adoption accelerates. 🤝 IP Group plc has supported Intrinsic from seed stage, backing its ambition to address fundamental bottlenecks in conventional memory and helping enable scalable, lower‑energy AI infrastructure. 📖 Full case study: ipgroupplc.com/our-portfolio/…

Great piece on portfolio company Barocal by @TimDe_Chant in @TechCrunch 🚀❄️🔥

🎉 Congratulations to portfolio company Barocal on its successful $10m fundraising 🚀❄️🔥 A fantastic milestone for the team as they scale their solid‑state cooling and heating technology with the potential for real climate impact 🌍🌱 We’re proud to have supported the round alongside @WorldFund , @Breakthrough and @UCamEnterprise.

🔗 ipgroupplc.com/news-and-event…

🎉 We’re delighted to welcome new portfolio company Hypervision Surgical as it announces an oversubscribed £17m Series A. 📈 🩺 Hypervision Surgical is pioneering real-time hyperspectral vision for surgery, helping power a new layer of surgical intelligence by giving surgeons richer real-time insight into tissue. 🚀 The funding will support commercial deployment, expand clinical adoption and advance next‑generation sensing technology towards a scalable, cloud‑enabled surgical intelligence platform.